According to the resolution of the 2023 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest ...
Growth and profitability despite large impact from the global antibiotics shortage and continued expansion of pipeline
EQL Pharma AB (publ) will publish its quarterly report for the third quarter, 2023/24, on Tuesday, February 13[th], after stock markets closing. At 10.00 (CET) 14[th] February, the company will gi...
EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles
Every year, Dagens Industri appoints Sweden's fastest growing company to the so-called Gazelle company. It is an award to support and encourage Swedish entrepreneurs to grow.
Growth despite large impact from the global antibiotics shortage, several important MA approvals and expansion of pipeline